Financial Performance - Total revenues for the three months ended September 30, 2023, were $589.1 million, an increase from $553.3 million in the same period last year, representing a growth of 6.5%[12] - Gross profit for the three months ended September 30, 2023, was $204.9 million, compared to $183.9 million in the prior year, reflecting a gross margin increase from 33.3% to 34.8%[12] - The net loss for the three months ended September 30, 2023, was $33.0 million, compared to a net income of $7.2 million in the same period last year, marking a significant decline[12] - Total revenues for the three months ended September 30, 2024, were $589.1 million, a 6.5% increase from $553.3 million in the same period of 2023[48] - For the nine months ended September 30, 2024, total revenues reached $1.75 billion, compared to $1.67 billion for the same period in 2023, reflecting a growth of approximately 4.8%[48] Expenses and Costs - Operating expenses for the three months ended September 30, 2023, totaled $196.6 million, up from $161.1 million, indicating a rise of 22% year-over-year[12] - The company incurred interest expense of $24.7 million for the three months ended September 30, 2023, compared to $24.2 million in the prior year[12] - The total cost of goods sold for the three months ended September 30, 2023, was $384.3 million, an increase from $369.4 million year-over-year[12] - SG&A expenses increased to $162.7 million for the three months ended September 30, 2024, up 9.5% from $148.6 million in the same period last year, primarily due to higher compensation and dealer fees[199][200] - Restructuring, strategic transaction, and integration expenses were $16.8 million for the three months ended September 30, 2024, compared to $7.2 million for the same period in 2023[203] Research and Development - Research and development expenses for the three months ended September 30, 2023, were $21.0 million, slightly up from $20.9 million year-over-year[12] - R&D expenses were $21.0 million for the three months ended September 30, 2024, a slight increase of 0.5% from $20.9 million in the same period in 2023, reflecting ongoing support for R&D projects[201] Cash Flow and Investments - Cash provided by operating activities for the nine months ended September 30, 2024, was $163.84 million, up from $74.93 million in 2023[20] - The company reported a net cash used in investing activities of $62.41 million for the nine months ended September 30, 2024, compared to $57.30 million in 2023[20] - Purchases of property, plant, and equipment totaled $55.29 million for the nine months ended September 30, 2024, compared to $53.96 million in 2023[20] Debt and Financing - The company entered into a Credit Agreement for $2.2 billion in senior secured credit facilities, including a $850 million Term Loan A and a $850 million Term Loan B[121] - The effective interest rates for Term Loan A and Term Loan B are 8.22% and 8.57%, respectively, as of September 30, 2024[142] - Total principal payments on the Term Loans for the nine months ended September 30, 2024, were $38.3 million, compared to $22.3 million for the same period in 2023[134] Assets and Liabilities - As of September 30, 2024, total assets amounted to $16,473 million, a decrease from $35,399 million as of December 31, 2023[72] - Total liabilities as of September 30, 2024, were $11,503 million, compared to $2,830 million as of December 31, 2023[72] - The carrying value of goodwill increased to $1,478,293 thousand as of September 30, 2024, from $1,472,446 thousand at the beginning of the year[104] Revenue Segmentation - Revenues from the Consumables segment for the three months ended September 30, 2024, were $264.9 million, up from $242.0 million in 2023, representing a growth of 9.4%[48] - Infusion Systems revenue increased to $159.8 million for the three months ended September 30, 2024, a 10.8% increase from $149.0 million in the same period last year[195] - Vital Care revenue rose to $164.5 million for the three months ended September 30, 2024, a 1.4% increase from $162.3 million in the same period in 2023, driven by higher sales of IV Solutions and Respiratory products[196][197] Legal and Compliance - The company is involved in various legal proceedings but does not expect any material adverse impact on its financial position[152] - The company is currently assessing the impact of new accounting standards on its consolidated financial statements and related disclosures[26] Strategic Initiatives - The company plans to continue focusing on strategic transactions and integration, with restructuring expenses amounting to $16.8 million for the three months ended September 30, 2023, compared to $7.2 million in the prior year[12] - The company is forming a Delaware LLC to transfer its IV Solutions product line, with Otsuka Pharmaceutical Factory America acquiring a 60% equity interest for approximately $200 million at closing[165]

Exhibit 99.1 ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., November 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP g ...

Group 1 - ICU Medical has consistently beaten earnings estimates, with an average surprise of 36.73% over the last two quarters [1] - In the most recent quarter, ICU Medical reported earnings of $1.56 per share, exceeding the expected $0.98 per share by 59.18% [1] - For the previous quarter, the company reported $0.96 per share against an estimate of $0.84 per share, resulting in a surprise of 14.29% [1] Group 2 - Earnings estimates for ICU Medical have been trending higher, supported by its history of earnings surprises [2] - The stock has a positive Zacks Earnings ESP of +2.67%, indicating bullish sentiment among analysts regarding its near-term earnings potential [3] - The combination of a positive Earnings ESP and a Zacks Rank 3 (Hold) suggests a high likelihood of another earnings beat [2][3] Group 3 - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [3] - A negative Earnings ESP does not necessarily indicate an earnings miss but can reduce the predictive power of the metric [3] - It is important for investors to check a company's Earnings ESP before quarterly releases to improve the chances of success [4]

Have you been paying attention to shares of ICU Medical (ICUI) ? Shares have been on the move with the stock up 27.6% over the past month. The stock hit a new 52-week high of $160 in the previous session. ICU Medical has gained 59.2% since the start of the year compared to the 11.1% move for the Zacks Medical sector and the 10.2% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earn ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are und ...

ICU Medical Inc (NASDAQ:ICUI) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants John Mills - Managing Partner Vivek Jain - CEO & Chairman of the Board Brian Bonnell - CFO & Treasurer Conference Call Participants Larry Solow - CJS Securities Kristen Stewart - CL King Brett Fishbin - KeyBanc Capital Markets Mike Matson - Needham & Company Jayson Bedford - Raymond James Operator Good afternoon, ladies and gentlemen, and welcome to the ICU Medical Inc Second Quarter 2024 Earnings Co ...

ICU Medical (ICUI) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.88 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 59.18%. A quarter ago, it was expected that this medical device maker would post earnings of $0.84 per share when it actually produced earnings of $0.96, delivering a surprise of 14.29%. Over the last four quarters, th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------|---------------------| | For the transition period from: | | | Commission File No.: 0 ...

Exhibit 99.1 ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., August 7, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross pro ...

SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2024 earnings release and conference call. The Company will release its second quarter 2024 results on Wednesday, August 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, August ...